MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia

G Marconi, A Talami, MC Abbenante… - European Journal of …, 2020 - Wiley Online Library
G Marconi, A Talami, MC Abbenante, C Sartor, S Parisi, J Nanni, L Bertamini, S Ragaini…
European Journal of Haematology, 2020•Wiley Online Library
Introduction Clinical response and chemosensitivity of relapse or refractory AML patients
were evaluated after rescue and bridge‐to‐transplant MEC (mitoxantrone, etoposide, and
cytarabine) regimen. Methods and Patients Fifty‐five consecutive AML patients were treated
with MEC from 2009 to 2018. Chemosensitivity was evaluated by WT1 quantification.
Results 27/55 patients (49.1%) had AML resistant to induction and 28/55 patients (50.9%)
had AML relapse. 25/55 patients (45.5%) achieved a CR after one course of MEC, and 12 …
Introduction
Clinical response and chemosensitivity of relapse or refractory AML patients were evaluated after rescue and bridge‐to‐transplant MEC (mitoxantrone, etoposide, and cytarabine) regimen.
Methods and Patients
Fifty‐five consecutive AML patients were treated with MEC from 2009 to 2018. Chemosensitivity was evaluated by WT1 quantification.
Results
27/55 patients (49.1%) had AML resistant to induction and 28/55 patients (50.9%) had AML relapse. 25/55 patients (45.5%) achieved a CR after one course of MEC, and 12 patients (21.8%) achieved WT1 negativity. In 12 patients, a second MEC was administered. Four out of 12 patients improved significantly their response with the 2nd MEC. MEC was an effective bridge to transplant, 32/55 patients (58.2%) received an allogenic stem cell transplant. Median overall survival (OS) from MEC was 455 days (95% CI 307‐602 days.); patient with WT1 negative CR had the best OS (P<.000).
Conclusion
WT1 is a useful marker of chemosensitivity after MEC as rescue and bridge‐to‐transplant therapy.
Wiley Online Library
展开收起
被引用次数：6 相关文章 所有 6 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果